Skip to main content
. Author manuscript; available in PMC: 2013 Feb 15.
Published in final edited form as: Clin Cancer Res. 2012 Jan 6;18(4):1039–1050. doi: 10.1158/1078-0432.CCR-11-1429

Figure 5. IL-4-associated increase in intracellular and surface CD20 is associated with enhanced CD20 promoter activity and an increase in rituximab-associated CMC.

Figure 5

(A) Cells were incubated with IL-4 (5ng/ml) and harvested at indicated time points for total CD20 expression by Western blot analysis and surface CD20 expression by flow cytometry. Cells were incubated with RPMI 1640-10 media alone, or with 5ng/ml IL-4 for 48 hours before cells were: (B) lysed for CD20 promoter activity analysis in RRCL by luciferase assay; or (C) used to analyze rituximab-associated CMC by 51Cr release assay. (D) B-NHL cells were isolated by negative selection and treated with 5ng/ml of IL-4 for 48 hours before subjected to flow cytometric analysis for CD20 expression and 51Cr release assay for rituximab-associated CMC.